Ubiquiti Networks (NASDAQ:UBNT)‘s stock had its “outperform” rating restated by analysts at Sanford C. Bernstein in a research report issued to clients and investors on Thursday, Analyst RN reports. They currently have a $65.00 price target on the stock. Sanford C. Bernstein’s price target would suggest a potential upside of 47.13% from the company’s current price. Ubiquiti Networks Inc. (NASDAQ:UBNT) shares after opening at $45.57 moved to $48.91 on last trade day and at the end of the day closed at $44.42. Company price to sales ratio in past twelve months was calculated as 8.61 and price to cash ratio as 12.74. Ubiquiti Networks Inc. (NASDAQ:UBNT) showed a negative weekly performance of -18.84%.
Alnylam Pharmaceuticals (NASDAQ:ALNY) major shareholder Sanofi purchased 344,448 shares of the stock on the open market in a transaction that occurred on Tuesday, March 25th. The stock was purchased at an average cost of $66.88 per share, for a total transaction of $23,036,682.24. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares fell -5.20% in last trading session and ended the day on $61.74. ALNY return on equity ratio is recorded as -30.10% and its return on assets is -19.80%. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) yearly performance is 153.34%.
Darrell Cavens, the 41-year-old chief executive officer of Zulily (NASDAQ:ZU) Inc., has become a billionaire as the online retailer has rallied 58 percent this year. Zulily Inc. (NASDAQ:ZU) shares moved up 6.47% in last trading session and was closed at $51.97, while trading in range of $47.75 – $53.89. Zulily Inc. (NASDAQ:ZU) year to date (YTD) performance is 25.44%.
Biopharma Clovis Oncology Inc. (NASDAQ:CLVS) is reporting positive findings midway through a study of a lung-cancer treatment. Clovis Oncology Inc. (NASDAQ:CLVS) weekly performance is -11.99%. On last trading day company shares ended up $70.33. Clovis Oncology Inc. (NASDAQ:CLVS) distance from 50-day simple moving average (SMA50) is -5.92%. Analysts mean target price for the company is $101.17.